Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 intrathecal ALN-APP study in early-onset Alzheimer's disease
NL-OMON51311Phase 1Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mivelsiran in early-onset Alzheimer's disease (EOAD) (11 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoints: Frequency of adverse events in Part A, Safety and tolerability assessments in Part A and 2 more. Started Oct 2022; status: recruiting.
02
Drugs
mivelsiran
03
Conditions
early-onset Alzheimer's disease (EOAD)
Beyond the preview
Go deeper on NL-OMON51311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51311.